Hyundai ADM Bio's latest marketcap:
As of 04/30/2026, Hyundai ADM Bio's market capitalization has reached $448.43 M. According to our data, Hyundai ADM Bio is the 16117th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 448.43 M |
| Revenue (ttm) | 6.59 M |
| Net Income (ttm) | -13,599,574.4 |
| Shares Out | 54.76 M |
| EPS (ttm) | -0.32 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 03/30/2026 |
Hyundai ADM Bio's yearly market capitalization.
| Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 06/02/2026 | ₩352.13 B | $232.66 M | 170.17% | n/a |
| 12/30/2025 | ₩130.34 B | $88.57 M | 86.73% | 29202 |
| 12/30/2024 | ₩69.8 B | $46.77 M | 57.99% | 28450 |
| 12/28/2023 | ₩44.18 B | $34.02 M | 1.39% | 30371 |
| 12/29/2022 | ₩43.58 B | $34.42 M | -66.41% | 29384 |
| 12/30/2021 | ₩129.71 B | $108.95 M | 22589 |
Company Profile
About Hyundai ADM Bio Inc.
Hyundai ADM Bio Inc. is a leading contract research organization (CRO) specializing in clinical services across Asia. The company delivers comprehensive clinical development and pharmacovigilance solutions to support the pharmaceutical and biotechnology industries.
Core Services
- Clinical Development Services – Including medical writing, clinical operations, late-phase studies, data management, biostatistics, and regulatory affairs.
- Pharmacovigilance Services – Covering case processing, safety reporting, risk management plans, aggregate reporting, literature screening, and medical device vigilance.
- Quality Assurance Services – Ensuring compliance and operational excellence.
Innovative Medical Solutions
The company also specializes in the development, manufacturing, and commercialization of medical microneedle patches, offering advanced therapeutic and diagnostic solutions.
Company Background
Originally established as ADM Korea Inc. in 2003, the company rebranded to Hyundai ADM Bio Inc. in September 2024. Headquartered in Seoul, South Korea, it continues to expand its footprint in the clinical research and medical technology sectors.
Frequently Asked Questions
-
What is Hyundai ADM Bio's (KOSDAQ-187660) current market cap?As of 04/30/2026, Hyundai ADM Bio (including the parent company, if applicable) has an estimated market capitalization of $448.43 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Hyundai ADM Bio (KOSDAQ-187660) rank globally by market cap?Hyundai ADM Bio global market capitalization ranking is approximately 16117 as of 04/30/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.